+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer

Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer

Journal of Clinical Oncology 28(16): 2651-2652

(PDF emailed within 0-6 h: $19.90)

Accession: 055911462

Download citation: RISBibTeXText

PMID: 20421530

DOI: 10.1200/JCO.2010.28.5809

Related references

Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer. Cancer 107(9): 2180-2185, 2006

Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition. Cancer 110(5): 1003-1009, 2007

Reliability of prostate-specific antigen-marker in determining biochemical failure during the first 2 years after external beam radiation therapy and hormone therapy in patients with non-operated prostate cancer. Urologic Oncology 32(1): 30.E1-7, 2014

Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation Therapy. Yearbook of Oncology 2011: 117-118, 2011

Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. Journal of Clinical Oncology 28(16): 2653-2659, 2010

Prostate specific antigen psa as a marker of disease recurrence in 290 patients with prostate cancer treated with external beam radiation therapy ebrt. Journal of Urology 147(4 SUPPL): 444A, 1992

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. Journal of Clinical Oncology 17(1): 168-172, 1999

Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts. International Journal of Radiation Oncology, Biology, Physics 72(3): 782-791, 2008

Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Journal of Clinical Oncology 17(4): 1155-1155, 1999

Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report. Oncology Letters 11(1): 713-716, 2016

Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. Bju International 95(3): 285-290, 2005

The fall and rise of prostate-specific antigen: Kinetics of serum prostate-specific antigen level after radiation therapy for prostate cancer. Cancer (Philadelphia) 72(3): 832-842, 1993

Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. Journal of Urology 176(4 Pt 1): 1399-1403, 2006

Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?. Frontiers in Oncology 7: 157-157, 2017

Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. Cancer 95(2): 275-280, 2002